Erika P. Hamilton, MD
Sarah Cannon has announced the promotion of Erika P. Hamilton, MD, to Director of the institution’s Breast and Gynecologic Cancer Research Program. Over the past 3 years, Dr. Hamilton has been instrumental in the growth and success of the program.
“Erika has quickly become a recognized thought leader in the field of women’s cancer research by not only her research peers, but also the pharmaceutical and biotech industry for her contributions to drug development,” said Howard A. “Skip” Burris III, MD, Chief Medical Officer for Sarah Cannon.
Dr. Hamilton’s research focuses on novel therapies, personalized medicine, and immunotherapy. She will continue to care for patients at Sarah Cannon Research Institute and is an associate with Tennessee Oncology, PLLC. ■
